Jan 18, 2011 by Brian Orelli, PhDWill Vilazodone Gain FDA Approval This Week?Big rewards ahead at the end of the month.
Jan 18, 2011 by Brian Orelli, PhDUp 30%, Succeed Indeed!An aptly named clinical trial bodes well for Ariad Pharmaceuticals.
Jan 14, 2011 by Brian Orelli, PhDDon't Have a Stroke Over Merck's Heart DrugWelcome to pharma investing.
Jan 13, 2011 by Brian Orelli, PhDFDA Panel Gives Eli Lilly IndigestionEli Lilly's new acquisition causes a tummy ache.
Jan 13, 2011 by Brian Orelli, PhDThis Trendy Pharma Is Making a Stylish MoveMerck signs up a CRO to help with biosimilars.
Jan 12, 2011 by Brian Orelli, PhDDrugmaker Math: 4 Halves Beat 2 WholesEli Lilly and Boehringer Ingelheim hook up.
Jan 11, 2011 by Brian Orelli, PhDA Clear Drug-Development Path -- Times 2The FDA throws a fork in the road for Isis and Genzyme.
Jan 7, 2011 by Brian Orelli, PhDDendreon Heads Across the PondA pathway to Provenge approval in the EU.
Jan 6, 2011 by Brian Orelli, PhD$145 Million Down; Billions to GoSeattle Genetics signs up another partner.
Jan 5, 2011 by Brian Orelli, PhDSpectrum Pharma Jumps in With the Big Dogs Spectrum is developing biosimilars.
Jan 4, 2011 by Brian Orelli, PhDA Drug Deal an Options Trader Would LoveXOMA licenses its drug, but retains rights to buy it back.
Jan 3, 2011 by Brian Orelli, PhDClinical Trial Results Fail to InspireInspire Pharma gets cut in half after a cystic fibrosis trial failure.
Dec 31, 2010 by Brian Orelli, PhD2010 FDA Approvals and a Look AheadRecent history can help us handicap FDA decisions.
Dec 31, 2010 by Brian Orelli, PhD3 Biotech 2010 IPOs Worthy of a LookThese IPOs are worth a spot on your watchlist.
